EARS Auris Medical Holding Ltd.

0.8
+0.03  (+3%)
Previous Close 0.78
Open 0.76
Price To Book 0.28
Market Cap 2,655,318
Shares 3,302,634
Volume 31,502
Short Ratio
Av. Daily Volume 104,322
Stock charts supplied by TradingView

NewsSee all news

  1. Auris Medical Provides Update on Intranasal Betahistine Development Program

    Phase 1b trial with AM-201 proceeding as planned to data read-out in early May 2020Enrollment into Phase 2 trial with AM-125 impacted by COVID-19 pandemicCompany to report 2019 second-half and full year results and

  2. Auris Medical Provides Update on Ongoing Clinical Trials with Intranasal Betahistine

    Last subject had last treatment visit in Phase 1b trial with AM-201 in prevention of antipsychotic-induced weight gain and somnolence; data read-out expected for early May 2020Phase 2 trial with AM-125 in treatment of

  3. Auris Medical Highlights Publication of Study Results Demonstrating Betahistine's Antiepileptogenic and Anticonvulsant Activity in Murine Model

    Hamilton, Bermuda, February 25, 2020 - Auris Medical Holding AG (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous

  4. Auris Medical Announces Notice of Allowance for European Patent Application

    Received "Intention to Grant" notice from European Patent OfficeApplication covers invention of oral treatment for tinnitus Hamilton, Bermuda, January 10, 2020 – Auris Medical Holding Ltd. (NASDAQ:EARS), a

  5. Auris Medical Announces Formation of New Subsidiary for Development Projects in Tinnitus and Hearing Loss

    Hamilton, Bermuda, Dec. 30, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 HEALOS trial did not meet primary endpoint - November 28, 2017.
AM-111 HEALOS
Acute inner ear hearing loss
Phase 3 data released March 13, 2018 - primary endpoint not met. Noted April 25, 2019 that it intends to discuss a new Phase 2/3 trial with the FDA.
Keyzilen (AM-101)
Acute inner ear tinnitus
Phase 3 ASSENT trial terminated - November 28, 2017.
AM-111 ASSENT
Acute inner ear hearing loss
Phase 2 trial (REACH) enrollment pending funding.
AM-111 REACH
Surgery-induced hearing loss
Phase 3 trial did not meet primary endpoints
AM-101 (Keyzilen) - TACTT2
Acute inner ear tinnitus
Phase 2 interim analysis due 3Q 2020.
AM-125
Vertigo
Phase 1b data from second part of trial due early-May 2020.
AM-201
Healthy volunteers

Latest News

  1. Auris Medical Provides Update on Intranasal Betahistine Development Program

    Phase 1b trial with AM-201 proceeding as planned to data read-out in early May 2020Enrollment into Phase 2 trial with AM-125 impacted by COVID-19 pandemicCompany to report 2019 second-half and full year results and

  2. Auris Medical Provides Update on Ongoing Clinical Trials with Intranasal Betahistine

    Last subject had last treatment visit in Phase 1b trial with AM-201 in prevention of antipsychotic-induced weight gain and somnolence; data read-out expected for early May 2020Phase 2 trial with AM-125 in treatment of

  3. Auris Medical Highlights Publication of Study Results Demonstrating Betahistine's Antiepileptogenic and Anticonvulsant Activity in Murine Model

    Hamilton, Bermuda, February 25, 2020 - Auris Medical Holding AG (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous

  4. Auris Medical Announces Notice of Allowance for European Patent Application

    Received "Intention to Grant" notice from European Patent OfficeApplication covers invention of oral treatment for tinnitus Hamilton, Bermuda, January 10, 2020 – Auris Medical Holding Ltd. (NASDAQ:EARS), a

  5. Auris Medical Announces Formation of New Subsidiary for Development Projects in Tinnitus and Hearing Loss

    Hamilton, Bermuda, Dec. 30, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and

  6. Auris Medical Announces Positive Interim Results from AM-201 Phase 1b Study in Antipsychotic-Induced Weight Gain

    Hamilton, Bermuda, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and

  7. Auris Medical Receives FDA and EMA Guidance for Keyzilen® Late-Stage Clinical Development Program

    Hamilton, Bermuda, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology

  8. Auris Medical Announces Notices of Allowance for U.S. and European Patent Applications Covering Intranasal Betahistine

    Hamilton, Bermuda, Sept. 11, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology

  9. Auris Medical Announces Appointment of New Chief Financial Officer

    Hamilton, Bermuda, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology

  10. Auris Medical Announces Formation of Scientific Advisory Board for Tinnitus Programs

    Hamilton, Bermuda, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and